drugset
drugset / Trial / NCT03133130

Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers

NCT03133130 ↗

Phase 1 Completed 32 enrolled Hugel
RandomizedParallel-groupSingle-blindTreatment

Summary

Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers

Timeline

Start
2017-07-31
Primary completion
2018-02-14
Completion
2018-02-14

Drugs

EvaluationDrugModalityDoseRoute
Subject BMT101 Small interfering RNA (siRNA) — Other

Indications

reactive cutaneous fibrous lesion